NCT01635387

RAAS Inhibitor Drugs in Dialysis Patients

Upstream Use of Aliskiren in Hypertensive Haemodialysis Patients: Effects on Cardiovascular Outcomes

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 350 (estimated)
• Sponsor: University of Campania Luigi Vanvitelli · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Hypertensive haemodialysis patients are at high risk for cardiovascular events. This study was undertaken to ascertain whether the upstream of aliskirne, a direct renin inhibitor improves mortality and cardiovascular outcomes in these high-risk population.

Conditions

• Hypertension
• End Stage Renal Disease

Interventions

Type	Name	Description
DRUG	aliskiren	150 mg once a day per 2 week with forced uptitration to 300 mg once a day, if tolerated

Timeline

• Start date: 2010-02-01
• Primary completion: 2012-09-01
• Completion: 2012-09-01
• First posted: 2012-07-09
• Last updated: 2012-07-09